Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

EWS–FLI1 Retargets BAF Chromatin Remodeling Complexes in Ewing Sarcoma

DOI: 10.1158/2159-8290.CD-RW2017-165 Published October 2017
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: BAF recruitment to GGAA microsatellites activates the Ewing sarcoma transcriptional program.

  • Mechanism: The prion-like domain in EWS–FLI1 is required for phase transitions that promote enhancer activation.

  • Impact: Prion-like domains can retarget chromatin remodeling complexes to promote oncogenic gene expression.

In Ewing sarcoma, a chromosomal translocation generates the oncogenic fusion protein EWS–FLI1, which drives tumorigenicity. EWS–FLI1 contains the ETS DNA binding domain of FLI1, but the functional role of the EWSR1 portion is not well understood, although it has been linked to transcriptional activation. EWS–FLI1 has been shown to act as a pioneer transcription factor by binding to GGAA microsatellite repeats to establish active enhancers and promote expression of Ewing sarcoma genes. However, the mechanism by which EWS–FLI1 facilitates chromatin remodeling has not been elucidated. Boulay, Sandoval, and colleagues found that both wild-type EWSR1 and EWS–FLI1 interacted with subunits of the BRG1/BRM-associated factor (BAF) chromatin remodeling complex (also known as SWI/SNF). Mechanistically, EWS–FLI1, but not wild-type FLI1, recruited BAF complexes to tumor-specific GGAA microsatellite repeat enhancers to facilitate chromatin opening and EWS–FLI1-mediated target gene expression. EWSR1 contains an intrinsically disordered low-complexity prion-like domain that confers phase transition properties, which were required for EWS–FLI1 to act as a pioneer transcription factor. Tyrosine residues in the prion-like domain of EWS–FLI1 were necessary for phase transitions and enabled binding to GGAA microsatellites, BAF recruitment, and activation of tumor-specific de novo enhancers. Consistent with these findings, fusing small fragments of the disordered EWSR1 prion-like domain to the C-terminus of FLI1 was sufficient to recapitulate the chromatin binding and gene expression program of full length EWS–FLI1. In addition to elucidating a mechanism by which the EWSR1 portion of EWS–FLI1 can promote chromatin remodeling to facilitate the oncogenic effects of EWS–FLI1, these findings reveal that prion-like domains can promote retargeting of chromatin remodeling complexes to establish and maintain oncogenic gene expression programs. Further, these results reveal a role for the BAF complex in promoting tumorigenesis in the absence of genetic alterations in BAF subunits.

Boulay G, Sandoval GJ, Riggi N, Iyer S, Buisson R, Naigles B, et al. Cancer-specific retargeting of BAF complexes by a prion-like domain. Cell 2017 Aug 24 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2017 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 7 (10)
October 2017
Volume 7, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EWS–FLI1 Retargets BAF Chromatin Remodeling Complexes in Ewing Sarcoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
EWS–FLI1 Retargets BAF Chromatin Remodeling Complexes in Ewing Sarcoma
Cancer Discov October 1 2017 (7) (10) 1060; DOI: 10.1158/2159-8290.CD-RW2017-165

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EWS–FLI1 Retargets BAF Chromatin Remodeling Complexes in Ewing Sarcoma
Cancer Discov October 1 2017 (7) (10) 1060; DOI: 10.1158/2159-8290.CD-RW2017-165
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Ewing Sarcoma

  • Ewing Sarcoma Gene Fusions Can Be Generated via Chromoplexy
  • Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors
Show more Ewing Sarcoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement